Atlas Trials

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Clinical trial NCT04989621 · RECRUITING

Trial details

NCT number
NCT04989621
Sponsor
Sun Yat-sen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Follicular LymphomaRelapsed and Refractory Follicular Lymphoma
Start date
2021-08-01
Primary completion
2026-08-01
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.